Mithra Announces Injectable Contrat with Midas Pharma

  • Mithra closes contract with Midas Pharma for development and potential manufacturing of sterile injectable
  • Strong validation by reputable partner of know-how and capabilities of Mithra CDMO

Liège, Belgium, 16 May 2018 – Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, today announces a contract with Midas Pharma for the development of a sterile injectable product at the Mithra CDMO . Midas Pharma, based in Germany, is a full-service provider and a leader in the sourcing and supplying of intermediates, APIs (Active Pharmaceutical Ingredients), FDFs (Finished Dosage Forms) and dossiers for finished products. The company is present in 10 countries and works with generic pharma players, big pharma companies as well as biotech firms.